Reviewing Cytek Biosciences (NASDAQ:CTKB) and Many Bright Ideas Technologies (OTCMKTS:MBGNF)

Many Bright Ideas Technologies (OTCMKTS:MBGNF) and Cytek Biosciences (NASDAQ:CTKB) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations and dividends.

Profitability

This table compares Many Bright Ideas Technologies and Cytek Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Many Bright Ideas Technologies	N/A	N/A	N/A
Cytek Biosciences	-38.98%	-12.40%	-9.17%

Insider & Institutional Ownership

69.5% of Cytek Biosciences shares are held by institutional investors. 10.4% of Cytek Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Many Bright Ideas Technologies and Cytek Biosciences”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Many Bright Ideas Technologies	N/A	N/A	N/A	N/A	N/A
Cytek Biosciences	$201.49 million	3.06	-$66.54 million	($0.62)	-7.65

Many Bright Ideas Technologies has higher earnings, but lower revenue than Cytek Biosciences.

Analyst Ratings

This is a breakdown of recent recommendations for Many Bright Ideas Technologies and Cytek Biosciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Many Bright Ideas Technologies	0	0	0	0	0.00
Cytek Biosciences	1	2	3	0	2.33

Cytek Biosciences has a consensus price target of $5.56, indicating a potential upside of 17.35%. Given Cytek Biosciences’ stronger consensus rating and higher possible upside, analysts clearly believe Cytek Biosciences is more favorable than Many Bright Ideas Technologies.

Summary

Cytek Biosciences beats Many Bright Ideas Technologies on 6 of the 9 factors compared between the two stocks.

About Many Bright Ideas Technologies

Many Bright Ideas Technologies Inc. does not have significant operations. It was previously engaged in the life science business with a focus on the commercialization of prognostic genomic-based tests for non-small-cell lung cancer. It focuses on the commercialization of technologies in various industrial sectors. The company is headquartered in Vancouver, Canada.

About Cytek Biosciences

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.